Idiopathic Dilated Cardiomyopathy Associated with Bicavitary Thrombi: Case Report, Diagnostic Approach and Literature Review
Main Article Content
Abstract
Dilated cardiomyopathy is considered as a dysfunction of the left ventricle systolic function or even both ventricles associated with myocardial dilation. Approximately 50% of cases have an identifiable cause such as genetic mutations, infectious, autoimmune or metabolic diseases, among others. When the origin of dilated cardiomyopathy is not identified, it is considered idiopathic, which constitutes the other 50% of cardiomyopathies. The diagnostic approach is based on laboratory and image studies trying to identify the known causes of dilated cardiomyopathy, the treatment consists in those cases of known etiology cardiomyopathy in the treatment of the underlying disease as well as the heart failure if it presents, if the etiology is unknown we only focus in improve the symptoms caused by cardiomyopathy.
We present a case of a 27-year-old man with history of sudden cardiac death in a second degree relative, who initially presented signs of heart failure with later pulmonary thromboembolism secondary to biventricular intracardiac thrombi. A complete diagnostic approach was performed, ruling out genetic and non-genetic causes of dilated cardiomyopathy, without being perform an endomyocardial biopsy to complete the diagnostic approach due to the risk that the procedure involved and the patient's refusal.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Heymans, Stéphane et al. Miocardiopatía dilatada: causas, mecanismos y enfoques de tratamiento actuales y futuros. The Lancet, volumen 402, número 10406, 998 – 1011
II. Fatkin D, Calkins H, Elliott P, James CA, Peters S, Kovacic JC. Contemporary and Future Approaches to Precision Medicine in Inherited Cardiomyopathies: JACC Focus Seminar 3/5. J Am Coll Cardiol. 2021 May 25;77(20):2551-2572. doi: 10.1016/j.jacc.2020.12.072. PMID: 34016267.
III. Costabel, Juan Pablo, Mandó, Florencia, & Avegliano, Gustavo. (2018). Miocardiopatía dilatada: ¿cuándo y cómo proceder a la investigación etiológica?. Revista Uruguaya de Cardiología, 33(3), 231-251. https://doi.org/10.29277/cardio.33.3.18
IV. Boned BP, Marco LC, Callejas GI. Miocardiopatía dilatada: Presentación de un caso clínico. Arch Med Fam. 2023;25(2):103-106.
V. Orphanou N, Papatheodorou E, Anastasakis A. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart Fail Rev. 2022 Jul;27(4):1173-1191. doi:10.1007/s10741-021-10139-0. Epub 2021 Jul 14. PMID: 34263412; PMCID: PMC8279384
VI. Hazebroek M, Dennert R, Heymans S. Idiopathic dilated cardiomyopathy: possible triggers and treatment strategies. Neth Heart J. 2012 Aug;20(7-8):332-5. doi: 10.1007/s12471-012-0285-7. PMID: 22618228; PMCID: PMC3402574.
VII. Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Chronic Chagas Heart Disease Management: From Etiology to Cardiomyopathy Treatment. J Am Coll Cardiol. 2017 Sep 19;70(12):1510-1524. doi: 10.1016/j.jacc.2017.08.004. PMID: 28911515.
VIII. Day E, Rudd JHF. Alcohol use disorders and the heart. Addiction. 2019 Sep;114(9):1670-1678. doi: 10.1111/add.14703. Epub 2019 Jul 15. PMID: 31309639; PMCID: PMC6771559.
IX. Verdonschot JAJ, Hazebroek MR, Derks KWJ, et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long¬term life¬threatening arrhythmias. Eur Heart J 2018; 39: 864–73.
X. Bozkurt, B., Colvin, M., Cook, J., Cooper, L. T., Deswal, A., Fonarow, G. C., Francis, G. S., Lenihan, D., Lewis, E. F., McNamara, D. M., Pahl, E., Vasan, R. S., Ramasubbu, K., Rasmusson, K., Towbin, J. A., Yancy, C., & American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research (2016). Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation, 134(23), e579–e646. https://doi.org/10.1161/CIR.0000000000000455
XI. Vissing CR, Rasmussen TB, Dybro AM, et al. Dilated cardiomyopathy caused by truncating titin variants: long-term outcomes, arrhythmias, response to treatment and sex differences. J Med Genet 2021; 58: 832–41.
XII. Marin-Neto JA et al. Actualización de la enfermedad de Chagas en su centenario. Rev Esp Cardiol. 2009;62(11):1211-6
XIII. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). (1999). Lancet (London, England), 353(9169), 2001–2007.
XIV. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. (1999). Lancet (London, England), 353(9146), 9–13.
XV. Singer, I., Al-Khalidi, H., Niazi, I., Tchou, P., Simmons, T., Henthorn, R., Holroyde, M., & Brum, J. (2004). Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. Journal of the American College of Cardiology, 43(1), 39–43. https://doi.org/10.1016/j.jacc.2003.07.033
XVI. Al-Khatib, S. M., Hellkamp, A. S., Fonarow, G. C., Mark, D. B., Curtis, L. H., Hernandez, A. F., Anstrom, K. J., Peterson, E. D., Sanders, G. D., Al-Khalidi, H. R., Hammill, B. G., Heidenreich, P. A., & Hammill, S. C. (2014). Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. JAMA, 311(21), 2209–2215. https://doi.org/10.1001/jama.2014.5310
XVII. Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., McNulty, S. E., Clapp-Channing, N., Davidson-Ray, L. D., Fraulo, E. S., Fishbein, D. P., Luceri, R. M., Ip, J. H., & Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators (2005). Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England journal of medicine, 352(3), 225–237. https://doi.org/10.1056/NEJMoa043399
XVIII. Weintraub, R. G., Semsarian, C., & Macdonald, P. (2017). Dilated cardiomyopathy. Lancet (London, England), 390(10092), 400–414. https://doi.org/10.1016/S0140-6736(16)31713-5
XIX. Zhu X, Wang Z, Ferrari MW, Ferrari-Kuehne K, Bulter J, Xu X, Zhou Q, Zhang Y, Zhang J. Anticoagulation in cardiomyopathy: unravelling the hidden threat and challenging the threat individually. ESC Heart Fail. 2021 Dec;8(6):4737-4750. doi: 10.1002/ehf2.13597.
XX. Mischie AN, Chioncel V, Droc I, Sinescu C. Anticoagulation in patients with dilated cardiomyopathy, low ejection fraction, and sinus rhythm: back to the drawing board. Cardiovasc Ther. 2013 Oct;31(5):298-302. doi: 10.1111/1755-5922.12019.
XXI. Jacobson, A. M., & Darrah, J. R. (2020). Biventricular Thrombi in Substance-Induced Dilated Cardiomyopathy. CASE (Philadelphia, Pa.), 4(3), 170–174. https://doi.org/10.1016/j.case.2020.01.007
XXII. Vaitkus, P. T., & Barnathan, E. S. (1993). Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. Journal of the American College of Cardiology, 22(4), 1004–1009. https://doi.org/10.1016/0735-1097(93)90409-t
XXIII. McCarthy, C. P., Vaduganathan, M., McCarthy, K. J., Januzzi, J. L., Jr, Bhatt, D. L., & McEvoy, J. W. (2018). Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment. JAMA cardiology, 3(7), 642–649. https://doi.org/10.1001/jamacardio.2018.1086
XXIV. Smetana, K. S., Dunne, J., Parrott, K., Davis, G. A., Collier, A. C. S., Covell, M., & Smyth, S. (2017). Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series. Journal of thrombosis and thrombolysis, 44(4), 519–524. https://doi.org/10.1007/s11239-017-1560-7
XXV. Elikowski, W., Małek-Elikowska, M., Fertała, N., Zawodna, M., & Kruzel, K. (2018). Fast apixaban-related resolution of left ventricular thrombi in a patient with dilated cardiomyopathy. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 44(259), 19–22.
XXVI. Iwano, T., Yunoki, K., Tokunaga, N., Shigetoshi, M., Sugiyama, H., Yamamoto, H., Kondo, J., Nakai, M., Okada, M., & Matsubara, H. (2016). A case of biventricular thrombi in a patient with dilated cardiomyopathy: Utility of multimodality imaging for diagnosis and management of treatment strategy. Journal of cardiology cases, 15(3), 91–94. https://doi.org/10.1016/j.jccase.2016.10.013